Cargando…

Itraconazole in chronic pulmonary aspergillosis: In whom, for how long, and at what dose?

Detalles Bibliográficos
Autores principales:	Maturu, Venkata Nagarjuna, Agarwal, Ritesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502192/ https://www.ncbi.nlm.nih.gov/pubmed/26180377 http://dx.doi.org/10.4103/0970-2113.159523

Ejemplares similares

P080 Comparison of efficacy of innovator molecule of itraconazole with generic forms of itraconazole in treatment naïve subjects with chronic pulmonary aspergillosis
por: Sehgal, Inderpaul, et al.
Publicado: (2022)

The minimal important difference of six-minute walk test in subjects with chronic pulmonary aspergillosis treated with six-months of oral itraconazole
por: Sehgal, Inderpaul S., et al.
Publicado: (2023)

Diagnosis of Chronic Pulmonary Aspergillosis: Which Is the Best Investigation?
por: Sehgal, Inderpaul Singh, et al.
Publicado: (2023)

Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India
por: Agarwal, Ritesh, et al.
Publicado: (2014)

Congenital isolated unilateral hypoplasia of the left pulmonary artery: A rare incidental anomaly in an elderly female
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis
por: Olum, Ronald, et al.
Publicado: (2020)

Emergency airway management – by whom and how?
por: Sollid, S. J. M., et al.
Publicado: (2016)

Special Issue: Chronic Pulmonary Aspergillosis
por: Kosmidis, Chris
Publicado: (2022)

Disentangling what works best for whom in comorbidity
por: Glozier, Nick, et al.
Publicado: (2022)

VIEWPOINT: What counts as online patient feedback, and for whom?
por: Dudhwala, Farzana, et al.
Publicado: (2017)

Antisynthetase syndrome: An under-recognized cause of interstitial lung disease
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2016)

New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis
por: Duret, Christophe, et al.
Publicado: (2012)

To immunosuppress: whom, when and how? That is the question with COVID-19
por: Winthrop, Kevin L, et al.
Publicado: (2020)

In search of the optimal proteosome inhibitor. How, when and for whom?
por: Engelhardt, Monika, et al.
Publicado: (2021)

Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases
por: Horiuchi, Hiroshi, et al.
Publicado: (2022)

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Pediatric Percutaneous Endoscopic Gastrostomy in Korea - When? By Whom? How?
por: Lee, Yoon
Publicado: (2022)

Inflammatory myofibroblastic tumor of the lung in pregnancy mimicking carcinoid tumor
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2016)

Aspergillosis with pulmonary echinococcosis
por: Gupta, Nalini, et al.
Publicado: (2006)

Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology
por: Shadambikar, Gauri, et al.
Publicado: (2021)

Allergic bronchopulmonary aspergillosis or pulmonary tuberculosis: A case of mistaken identity?
por: Muthu, Valliappan, et al.
Publicado: (2015)

Idiopathic pleuroparenchymal fibroelastosis presenting as bilateral spontaneous pneumothorax: A case report
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2019)

The future … to whom it belongs?()
por: Abrahão, Marcio
Publicado: (2016)

To Whom It May Concern
Publicado: (1888)

What works and for whom? Individual patient data meta-analyses in global nutrition research
por: Sudfeld, Christopher R, et al.
Publicado: (2021)

Clinical experience with low-dose itraconazole in chronic idiopathic cough
por: Ogawa, Haruhiko, et al.
Publicado: (2013)

Prevalence of Vitamin D Deficiency in Treatment-Naïve Subjects with Chronic Pulmonary Aspergillosis
por: Sehgal, Inderpaul Singh, et al.
Publicado: (2020)

Credit to Whom Credit Is Due
Publicado: (1871)

Credit to Whom Credit Is Due
Publicado: (1853)

Credit to Whom Credit Is Due
Publicado: (1855)

To Whom Belongs the Honor of Discovery?
Publicado: (1893)

Credit to Whom Credit Is Due
Publicado: (1888)

Credit to Whom Credit Is Due
Publicado: (1883)

P408 Evaluation of fungal serum biomarkers in the diagnosis and for monitoring patients with post tuberculosis chronic pulmonary aspergillosis
por: Singh, Shreya, et al.
Publicado: (2022)

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
por: McCurdy, Shannon R., et al.
Publicado: (2021)

Person‐centred care in primary care: What works for whom, how and in what circumstances?
por: Ahmed, Anam, et al.
Publicado: (2022)

Allergic bronchopulmonary aspergillosis causing bendopnea
por: Handa, Ajay, et al.
Publicado: (2017)

Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions
por: Ahn, Sang Hoon, et al.
Publicado: (2010)

Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis
por: Dhoot, Dhiraj, et al.
Publicado: (2023)

Diagnosis of Chronic Pulmonary Aspergillosis: Challenges and Limitations Response to “Diagnosis of Chronic Pulmonary Aspergillosis: Which Is the Best Investigation?” and “Diagnosis of Chronic Pulmonary Aspergillosis”
por: De Oliveira, Vítor Falcão, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3vq4sdpnf0fm3lh5hqgobtnsc